Latest PCOS Research: August 2026 Evidence Update

Three PCOS studies from the October 2026 round change what you might do this week. Exercise lowers testosterone, and 150 minutes a week or more works best. The berberine trials all failed a check for honest data. So there is no good proof that berberine works. And in a small trial, a probiotic did no better than a dummy pill for blood sugar.

This is the living PCOS research log from PCOS Meal Planner. PCOS is now also called PMOS, so we use both names. Each edition says what a study did, how big the effect was, and what it changes for your food, your movement or your next visit to the doctor. When a study changes nothing, we say so.

What changed advice in October 2026?

Nine of the 43 studies in this round matter most for food, movement and daily life. The table gives the size and the number that counts. The notes below give the limits.

Lifestyle network meta-analysis: each kind of exercise won on something

A network meta-analysis compares many options at once, even ones never tested head to head. This one, in Human Reproduction Update, pooled 43 randomised trials with 2,433 women with PCOS. It left out drug trials and any program shorter than two weeks.

Each type of movement won on a different measure. Aerobic exercise ranked best for waist-to-hip ratio and for systolic blood pressure, which fell by 3.49 mmHg. Mind-body exercise, the slow and breath-led kind, ranked best for insulin resistance. HOMA-IR, a score of insulin resistance, fell by 0.63. It also ranked best for fasting insulin, fasting glucose, triglycerides and LDL cholesterol. HIIT, short bursts of hard work with rests, ranked best for raising HDL, the "good" cholesterol.

The ketogenic diet cut waist size by 5.74 cm and BMI by 2.61 kg/m2. That sounds big, but it came from just 86 women in two study arms. The widest benefit came at about 480 to 1,012 MET-minutes a week. A MET is a unit of how hard your body works. For blood fats, the best match was 60 minutes of moderate to hard exercise, three times a week, for 13 to 17 weeks.

The authors rated the certainty of the evidence low or very low, and many estimates rest on two or three studies. So the lesson is to mix types, not to pick a winner. Walk, swim or cycle for waist and blood pressure, and add a slow, breath-led session for insulin. Do not start keto on the strength of 86 women. Our guide to the best exercise for PCOS turns this into a weekly plan.

Exercise on its own lowers testosterone, and the dose matters

A meta-analysis in the Journal of Obstetrics and Gynaecology Research pooled 22 randomised trials with 1,044 women. It only counted trials where exercise was the one change. Exercise lowered total and free testosterone, fasting insulin and HOMA-IR, and it raised HDL cholesterol.

Two details are worth a note. Exercise of 150 minutes a week or more gave larger drops in total testosterone. Moderate to low intensity raised SHBG, the protein that binds testosterone so less of it is free to act. Women who were not obese had larger testosterone drops than women who were.

The abstract does not give the pooled effect sizes, and trials ran up to July 2025. Still, it agrees with the August review further down this page. Thirty minutes, five days a week, gets you to 150. It does not need to be hard to count.

A nine-strain probiotic did not help blood sugar

This was a 12-week double-blind trial in Nutrients. Fifty women with PCOS took a nine-strain probiotic at 1 billion CFU a day, or a placebo. The team checked fasting and 2-hour glucose and insulin, HOMA-IR, and blood fats.

There were no clear differences between the groups on any of them. A second analysis that included all 50 women gave the same answer. Seven women did not finish, six of them in the probiotic group.

The trial is small. The authors say a real effect cannot be ruled out, and this is a second look at a trial built for other outcomes. But if you bought a probiotic to fix insulin resistance, this is the best test so far, and it found nothing. Fibre from beans, oats and vegetables feeds gut bacteria too, for less money. For strains with better data, see our probiotic strain guide.

CoQ10 added to inositol looked better than inositol alone

This study, also in the Journal of Obstetrics and Gynaecology Research, looked back at the records of 200 women with PCOS over 6 months. One group took myo-inositol alone. Two took myo-inositol plus CoQ10 at 100 mg or 200 mg. One group had no treatment.

Myo-inositol alone lowered HOMA-IR (beta -0.219) and testosterone (beta -3.145) against no treatment. Adding CoQ10 lowered HOMA-IR more, by -0.308 at 100 mg and -0.571 at 200 mg. For testosterone, 200 mg gave the biggest drop, at -5.325. Cycles became regular in 36.4% of the 200 mg group.

This was not a randomised trial. Women were not put in groups by chance, so the groups may have differed from the start. The authors ask for a proper trial. CoQ10 is a fair add-on to discuss with your doctor if you already take inositol, but it is not proven. Our CoQ10 versus inositol guide covers doses and cost.

The berberine trials could not be trusted

This one changes advice the most. Earlier reviews said berberine could match metformin for PCOS. A review in Advances in Therapy went back to the trials and checked them for honest data first.

All four trials that qualified, with 452 women in total, were rated high risk for compromised integrity. The problems included no trial registration, recruitment that moved too fast to be likely, and data that may have been used twice. The authors wrote to the trial teams and got no reply. So the review pooled nothing.

The trials did report better insulin, blood fats and androgens. The review says those results cannot be relied on. This does not prove berberine fails. It means no one has shown that it works. If you take it, you are paying for a guess. Our berberine for PCOS page has the full background.

Tirzepatide worked as well with PCOS as without it

Researchers in the Journal of the Endocrine Society looked at records from a UK online weight service. Of 54,114 women prescribed tirzepatide, 4,241 (7.84%) had PCOS.

At 10 months, women with PCOS had lost 19.40% of their body weight on average. Women without PCOS lost 18.74%, which was not a real difference. By 10 months, 57.66% of women with PCOS had lost 20% or more. Women with PCOS who stayed engaged with the service's digital support lost 3.42% more.

Only 40 women with PCOS reached the 10-month mark, and PCOS was self-reported. People who stay in a paid service may do better than those who leave. Even so, it suggests PCOS does not blunt the drug. Our semaglutide versus tirzepatide guide compares the two.

Diet coaching raised food variety and cut visceral fat

This study in Nutrition followed 50 women with PCOS, aged 18 to 30, in Lahore, Pakistan, for 6 months. They got one-to-one diet advice at the start and at 3 months.

The dietary diversity score, a count of food groups eaten, rose from 2.94 to 5.10. The body composition score rose from 62.94 to 64.72. The visceral fat reading fell from 12.74 to 11.74.

There was no control group, so some of the change could have happened anyway. But the target is simple, and you can use it today. Count the food groups on your plate and add one. Beans, nuts, seeds and a new vegetable all count.

Your BMI says more about metabolic risk than your PCOS type

The Rotterdam rules split PCOS into four types, A to D. A study in the Journal of Endocrinological Investigation asked which tells you more about risk: the type, or BMI. It used 1,314 white women of reproductive age from an Italian registry.

The four types did not differ in BMI or in rates of high blood fats, poor glucose control, high blood pressure or metabolic syndrome. Anxiety scores were highest in type A. Grouping by BMI showed clear gaps. Women with a BMI of 27 or more had more of every metabolic problem, and higher androgen and hair-growth scores.

This is one snapshot in time, and in one ethnic group. It does not mean lean women are safe, as the heart section below shows. It does mean your weight and waist are worth tracking, not your letter. See our guides to PCOS body fat percentage and lean PCOS treatment.

Your androgen result can depend on the lab method

Labs test testosterone and androstenedione in two main ways. CLIA is the common, cheaper immunoassay. LC-MS/MS is a more exact method based on mass. A study in Clinica Chimica Acta ran 495 samples through both and used the same cut-offs.

For testosterone, CLIA called 2.6% of samples high. LC-MS/MS called 12.1% high. For androstenedione it went the other way: 49.5% high on CLIA against 37.0% on LC-MS/MS. The two methods gave a different answer for 10.7% of testosterone tests and 32.7% of androstenedione tests. Some mismatch stayed even after samples close to the cut-off were removed.

The study does not set new cut-offs. It does give you a good question for your doctor: which method did my lab use? That matters most if your result sits near the line, or does not fit your symptoms. Read more in PMOS lab tests explained and our page on androstenedione and PCOS.

What does this round change on your plate?

Two things changed, and one was confirmed. The berberine and probiotic money can go back into food. Food variety is a target you can count. And the August rule still stands: do not pair a fat load with refined carbs in the same sitting.

Here is what a day built on those rules looks like, using real numbers from our recipe database.

• Breakfast: protein first, with at least three food groups. A pastry with coffee is the pairing the August evidence argues against.
• Lunch: Spicy Chickpea Chole at 244 calories and 11.3 g protein. The chickpeas add fibre and a food group.
• Dinner: Broiled Salmon with Asparagus at 453 calories and 42 g protein. The fat is omega-3 and it comes without refined carbs.
• Batch option: Red Lentil Sweet Potato Curry at 358 calories and 19 g protein.

What did the October studies find about heart and long-term risk?

PCOS raises the risk of heart attack and stroke, but the extra risk in years is small. A Danish study in the European Journal of Preventive Cardiology matched 25,513 women with PCOS to 102,052 women without it. Over 25 years, 3.4% of women with PCOS had a heart attack or stroke, against 2.0% of the others. After taking other risks into account, the hazard ratio was 1.53. It did not change with the pill, metformin, spironolactone or GLP-1 drugs. The authors call the absolute risk low and back early checks.

Another study used the same kind of insurance records. Published in the Journal of Clinical Endocrinology and Metabolism, it looked at race among 413,450 women with PMOS. Compared with white women, Asian women had lower heart and artery disease risk (aHR .65). Hispanic women had higher risk (aHR 1.21), and so did Black women (aHR 1.10). For Black women, the gap went away once home ownership, wealth and schooling were counted. So part of that risk comes from life conditions, not biology.

Two reviews pulled the heart story together. One in the Journal of Internal Medicine reports insulin resistance in 75% of lean and 95% of overweight women with PMOS. It cites close to 3-fold odds of type 2 diabetes (OR 2.9), with heart risk pulling away from about age 35. The other, in Cardiology in Review, cites a 2024 meta-analysis of over 300,000 women: odds of 2.50 for heart attack and 1.71 for stroke. It notes that heart guidelines do not yet list PCOS as a risk factor. Lean women carry risk too. Our page on PMOS, belly fat and heart disease covers what to track.

A review in Thrombosis Research covers blood clots. It says a clotting disorder, or clots in you or your family, should shape the choice of hormone treatment. It gives no new numbers. Tell your doctor about any clots in your family before you start the pill.

A nationwide insurance-records study in Fertility and Sterility compared 422,613 women with PCOS to 2,113,065 without it. Over about 3.6 years, women with PCOS had higher hazard ratios for breast (2.66), uterine (5.76), ovarian (4.38) and cervical (2.22) cancer. These are relative risks, and the abstract gives no absolute rates. Women with PCOS also see doctors more, which can raise how often a cancer is found. The European menopause guide covered below does not back extra cancer screening for PMOS alone. Keep to your normal screening, and report heavy or irregular bleeding.

What is new on fatty liver and PCOS?

An early drug trial cut liver fat in women with PCOS. Fatty liver, now called MASLD, is common in PCOS, but these women are rarely included in liver drug trials. A trial in Hepatology gave 60 women with PCOS and MASLD either saroglitazar 4 mg or a placebo for 24 weeks.

Liver fat fell by 14.81% on saroglitazar and rose by 1.96% on placebo, measured by MRI. A drop of 30% or more happened in 36.0% of the drug group against 8.7% on placebo. Liver enzymes and blood fats also improved. Side effects were similar in both groups, and none were serious.

This was a phase 2A trial, and the main analysis had just 25 women on the drug and 23 on placebo. It is a reason for a bigger trial, not a reason to ask for the drug. For what food can do for liver fat, read PMOS and fatty liver.

What did the October studies find on mood and mental health?

Depression and anxiety in PCOS were among the strongest-graded links in a huge new review. An umbrella review in European Neuropsychopharmacology graded 81 meta-analyses. Only 10 of 64 rates earned strong credibility. Two were about PCOS: depression in 37.0% and anxiety in 48.0%. If you feel low or on edge, that is part of the condition, and it is worth raising. See PMOS, anxiety and depression.

A review in the Journal of Health Psychology looked at 12 trials of mindfulness and talking therapy (CBT). Mindfulness trials covered 269 women and CBT trials 374. Both helped depression, anxiety and self-esteem. Effects on the body were mixed. Mindfulness lowered free testosterone and cortisol in some trials. This is the reverse of the August review, where body measures moved and mood scores did not. Put the two side by side and the safe read is that both kinds of benefit are possible, and neither is certain.

Not every app helps. A study in Gynecologie Obstetrique Fertilite and Senologie gave 54 women the SOLENCE PMOS app for 6 months. Quality of life, anxiety and depression scores did not improve, and one general quality-of-life score got worse. The study was small, and the app has since been changed.

A Chinese interview study in the Journal of Nutrition Education and Behavior spoke with 20 women with PCOS, 13 doctors and 4 nurses. It found three stages of habit change: intention, adoption and maintenance. Women could drop out at any stage. There are no effect sizes here. It is a useful reminder that a plan you can keep beats a perfect plan you drop.

What changed for teens with PCOS?

High androgens may be the first sign of PCOS in teens, ahead of irregular periods. A UK study that has tracked a group of children since birth, in the Journal of the Endocrine Society used data on 1,533 young people. Only 3% met the full PMOS rules, but 27% were "at risk". Of those, 18% had high androgens only and 9% had irregular periods only. Genes linked to PMOS went with high androgens alone (OR 1.22 per SD). They did not go with irregular periods alone (OR 0.98). So a teen with acne or extra hair is worth a closer look than one with late periods alone.

A meta-analysis in eBioMedicine pooled 51 studies with 4,892 teens to find the best blood tests. Three tests each scored an AUC of 0.74, which is fair. They were total testosterone, the free androgen index and the LH to FSH ratio. The best testosterone cut-off was 55.96 ng/dL. HOMA-IR did less well for spotting sugar risk, with an AUC of 0.65. Most of these results had moderate to low certainty.

Early adrenarche is when the glands above the kidneys start making androgens sooner than usual in childhood. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled 21 studies of 635 girls with it and 307 controls. After their first period, these girls had a higher BMI (by 1.4). They also had more insulin resistance and higher androgen levels. Most results were low certainty. If your daughter had early adrenarche, regular checks make sense. Our guide to PMOS in adolescence explains the teen rules.

What happens to PCOS at menopause, and why the PMOS name?

PCOS does not end at menopause, but how it shows up changes. A clinical guide from EMAS, the European Menopause and Andropause Society, in Maturitas sets out the rules. After menopause, PMOS is known from a past diagnosis or past cycle history, since periods and ovary scans no longer help. Heart and blood sugar risks remain, so checks should cover weight, waist, blood pressure, glucose and blood fats.

The guide makes three clear calls. New, severe or fast-rising androgen signs after menopause should be checked for other causes, not blamed on PMOS. PMOS alone does not call for extra breast, womb or ovarian cancer screening, or a separate bone scan plan. And PMOS alone is not a reason to refuse menopausal hormone therapy. Evidence in women past menopause is thin, so much of this comes from general menopause care.

A review in Endocrine Practice makes the same point in a different way. It suggests menopause is a shift in how PMOS shows up, not the end of it. It gives no new data. Read more in does PCOS go away after menopause.

On the name itself, a review in Advances in Nutrition explains how PMOS was chosen. The process took in 56 groups and over 14,000 survey replies. It also restates that diet is the first-line approach for metabolic risk in the international guideline. The new name points care toward food and metabolism, which is where most of what you control sits.

What did the October studies find on bones, eyes and the brain?

Bones looked normal in a Saudi study in Archives of Osteoporosis. It compared 72 women with PCOS to 72 women of the same age and BMI. Insulin resistance was clearly higher in PCOS, but bone density did not differ. Low vitamin D was just as common in both groups. This does not change advice. See osteopenia and PCOS for what helps bones.

Dry eye is mild at most. A meta-analysis in Current Eye Research pooled 13 studies with 639 women with PCOS. Symptom scores were 7.5 points worse, and the tear film broke up 3.1 seconds sooner on one test. Tear volume and the other stability test did not differ. Most women did not meet the criteria for dry eye disease, and certainty was low. More in PCOS and dry eye.

Any brain link seems to run through metabolism. A review in the Journal of the Endocrine Society found mild but repeated dips in memory and planning skills in PCOS. But direct evidence that PCOS raises dementia rates is limited and mixed. The authors think any risk runs through insulin resistance and obesity. So the advice is the same as for your heart. More in PCOS and dementia risk.

Which tests and markers did the October studies look at?

Lean PMOS looked almost the same as no PMOS in a big blood study. Using a hospital biobank, a study in the Journal of Assisted Reproduction and Genetics compared 403 women with PMOS to 4,365 without. Out of 71 blood markers, PMOS changed only 1 (1.4%) after adjustment. In women with a normal BMI, nothing differed except creatinine. In overweight women, 4 of 71 (5.6%) differed, mostly amino acids. This fits the August finding that resting tests can miss what is going on.

A small study of normal-weight women in Fertility and Sterility compared 21 women with PMOS to 19 controls. Insulin resistance in fat tissue was higher in PMOS. Yet HOMA-IR and a newer score, TyG-BMI, did not differ. Both are common screening scores, and both missed the gap. This is too small to change testing. It does show why a normal HOMA-IR is not the whole story.

Vitamin D was much lower in PMOS in a study in Annals of Medicine. Women with PMOS had 18.59 ng/mL against 37.95 ng/mL in 50 controls. The inflammation markers IL-6 and IL-8 were higher in PMOS, but they did not track vitamin D. With 44 women in a single snapshot, it cannot show cause. Ask for a vitamin D test if you have not had one.

Symptoms you can see may flag PCOS. A study in the Journal of Global Health compared 273 women with PCOS to 273 without in Bangladesh. The strongest links were irregular cycles (OR 4.93), weight gain out of the blue (OR 4.32) and hair on the jawline (OR 4.25). Sleep trouble (OR 2.62) and a waist wider than the hips (OR 2.47) also counted. After adjustment, acne, oily skin and hair loss did not.

A Chinese study in Frontiers in Endocrinology tested a thyroid score, TT4RI, in 264 women with a traditional Chinese medicine label of "phlegm-dampness". The score did a poor job of finding insulin resistance. This does not change advice.

What else came out this round?

Diet, drinks and skin

Three reviews covered food. A review in Ginekologia Polska says the Mediterranean diet is the best-proven anti-inflammatory eating pattern. It calls diet an add-on to treatment, not a swap for it. A review in Food Science and Nutrition covers plant flavonoids, found in fruit, tea and beans. It is mostly about lab mechanisms and food processing, and it has no new human results. Neither changes advice.

A review of drinks and skin in Clinics in Dermatology is more useful. It says spearmint tea lowers free testosterone in PCOS, but a clear skin or hair benefit is unproven. Sugary drinks and milk are linked with acne, though only in observational studies. See our PCOS acne diet.

Yoga and walking

A study in the Journal of Ayurveda and Integrative Medicine gave 30 women with PMOS 12 weeks of yoga. Hormones, body measures and blood fats improved, and blood glucose and fructose fell. There was no PMOS group without yoga to compare with, so we cannot tell how much was the yoga.

A study in the Journal of Exercise Science and Fitness put 80 women through 16 weeks of interval Nordic walking. Women with Rotterdam types one and two tended to respond more, with bigger drops in testosterone and DHEA-S. Types three and four responded less. The groups were only moderately stable, so treat this as a hint.

Weight medicines and surgery

GLP-1 drug use in PCOS has climbed fast. In Polish health records from 38,263 women, reported in Diabetes, Obesity and Metabolism, 11.9% had a GLP-1 or tirzepatide prescription. Starts within a year of diagnosis rose from 0.14% in 2018 to 5.97% in 2024. Only 11.5% of users had type 2 diabetes, which points to use for weight. A drug review in the Drug and Therapeutics Bulletin notes that GLP-1 data in PMOS are still limited. It says metformin gives modest weight loss. If you take one of these drugs, protein matters; see GLP-1 medications, protein and muscle loss.

A study in Obesity Surgery followed 111 women with PMOS for a year after sleeve gastrectomy. Median BMI fell from 38.5 to 26.7, and HbA1c from 5.8% to 5.2%. Most change came in the first three months. Women who lost weight fastest (57.7%) had better insulin and LDL. Nothing before surgery predicted who would be in that group. See PMOS and bariatric surgery.

Pain

One in five women with PMOS had a pain diagnosis in a huge global records study in eLife. The figure was 20.67%, and higher in Black (32.70%) and white (30.78%) women. Pain diagnoses fell after women started PMOS medicines. Period pain and pelvic pain are worth naming at your visit.

What we left out and why

Our weekly scan pulled 177 leads for this edition. We shortlisted 45 human studies that bear on daily life. The rest were letters, corrections, retractions, animal or cell work, network-pharmacology papers, or studies about fertility treatment results only.

Two of the 45 were left out too. One was a trial plan with no results yet, a fish oil trial due to run to 2028. The other was a letter with no abstract to check. That leaves the 43 studies on this page. Nine of them change advice. The other 34 are here so you can see what was looked at, including the ones that changed nothing.

Earlier in 2026: the August studies

The August edition reviewed 132 queued studies and picked seven, plus one inositol study. Their numbers and limits are kept here.

Exercise and testosterone. A three-level meta-analysis in PeerJ pooled 19 randomised trials with 1,018 women. Exercise lowered testosterone (g = -0.34), and aerobic work did most of it (g = -0.51). Three 30-minute aerobic sessions a week is the dose most of the trials used. Share this or share the dose.

Normal tests, real problem. A study in Diabetes, Obesity and Metabolism put 12 women with PCOS and 10 controls through insulin and fat challenges. There were zero baseline differences across 163 metabolites. The gap showed only under stress, and it stayed after eight weeks of exercise. A fasting test measures you at rest, which may be the wrong moment. Twelve women is small. For markers worth tracking, see PCOS blood markers and what to eat for each one. Share this, share the exercise point or share the lab point.

Mindfulness and androgens. A meta-analysis of 10 trials with 356 women found that yoga and meditation improved BMI, waist size, testosterone and hirsutism. Depression and anxiety scores did not change. Share this.

Tirzepatide added to metformin. In an open-label trial of 60 women over 16 weeks, weight fell 10.4 kg on the pair against 1.7 kg on metformin alone. Visceral fat fell 34.13 cm2 against 4.67 cm2. The drug was stopped at week 16, so the trial says nothing about whether the loss holds. For the muscle question, see GLP-1 medications, protein and muscle loss with PCOS. Share this or share the numbers.

Metformin and leptin. A Bayesian meta-analysis of 6 placebo-controlled trials found metformin lowered leptin, the fullness hormone (SMD -1.60). The size of the drop depended on starting BMI and fasting insulin. See taking metformin and inositol together for PCOS. Share this.

The pill and cholesterol. In the COMET-PCOS trial, 180 women were followed for 24 weeks. The pill raised HDL particles, and small LDL particles also rose. The authors said the data neither support nor refute heart risk. Do not change a prescription based on this. Share this.

Childhood sleep. The Raine Study followed 226 girls, and 37 had PCOS at 14. Trouble sleeping at age 10 carried an odds ratio of 2.95. It is a small study and shows a link, not a cause. If you snore or wake tired, read about sleep apnea and PCOS. Share this.

Inositol and body weight. A 2026 meta-analysis in Clinical Endocrinology pooled nine trials with 440 women. Inositol lowered total testosterone (SMD -1.30), most of all in women with a BMI under 25 (SMD -2.97). There was no clear gain in overweight women, and the authors called the subgroup result exploratory. See the best inositol ratio for PCOS and metformin and inositol together. Share this.

Frequently asked questions

What is the most important PCOS research from October 2026?

The berberine review. It checked all four berberine trials for honest data. All four, with 452 women, were rated high risk. So none could be used. That means there is no good proof that berberine works for PCOS. Exercise gave the best news. It lowers testosterone, and 150 minutes a week or more works best.

Does berberine work for PCOS?

No one has shown that it does. A 2026 review in Advances in Therapy found four trials, with 452 women. All four were rated high risk for data problems. Some had no trial record. Some may have used the same data twice. The trial teams did not reply. So the review could not pool any results. Berberine may still work. But the proof we had cannot be trusted.

How much exercise do I need for PCOS?

Aim for 150 minutes a week or more. A 2026 review of 22 trials found that this dose cut testosterone the most. That is 30 minutes, five days a week. A second review found the widest benefit at about 480 to 1,012 MET-minutes a week. Mix it up. Walking or cycling helped waist size and blood pressure. Slow, breath-led movement helped insulin.

Do probiotics help insulin resistance in PCOS?

Not in the best new test. In a 2026 trial, 50 women took a nine-strain probiotic or a dummy pill for 12 weeks. Blood sugar, insulin and blood fats did not differ between the groups. The trial was small, so a small effect is still possible. But do not count on a probiotic to fix insulin. Fibre from beans and oats is cheaper.

Is tirzepatide less effective if you have PCOS?

No. In UK records from a weight service, women with PCOS lost 19.40% of their weight by 10 months. Women without PCOS lost 18.74%. That gap was too small to count. More than half of the women with PCOS lost 20% or more. But only 40 women with PCOS got to 10 months, and PCOS was self-reported.

Why did my testosterone test come back normal when I have symptoms?

One reason is the lab method. A 2026 study ran 495 samples through two methods. The cheaper one, CLIA, called 2.6% of testosterone results high. The more exact one, LC-MS/MS, called 12.1% high. So the cheap test can miss a high result. Ask your doctor which method your lab used. This matters most if your result is close to the line.

Does my PCOS type matter for heart risk?

Less than your weight does. An Italian study of 1,314 women found the four PCOS types had the same rates of blood fat, blood sugar and blood pressure problems. Women with a BMI of 27 or more had more of all of them. Lean women still carry some risk. So track your waist, blood pressure and blood fats, not just your type.

Does PCOS raise the risk of heart attack?

Yes, but the risk in years is small. A Danish study followed 25,513 women with PCOS. Over 25 years, 3.4% had a heart attack or stroke. In women without PCOS, it was 2.0%. The risk did not change with the pill or metformin. Early checks of blood pressure, sugar and fats make sense.

Does PCOS go away after menopause?

No. A 2026 European menopause guide says the heart and blood sugar risks stay. Periods and ovary scans stop being useful, so a past diagnosis counts. PMOS alone does not mean extra cancer screening. It is not a reason to refuse hormone therapy either. New, strong signs of high androgens after menopause need a check for other causes.

How often is this page updated?

Whenever there is something worth reporting. A scan checks PubMed every week. We read the best human studies in full. Then we update this same page. If a month brings nothing that changes advice, the page will say so. We do not pad it.

Sources

October 2026 edition:

• Zhang et al., Human Reproduction Update, 2026: lifestyle network meta-analysis
• Zou et al., Journal of Obstetrics and Gynaecology Research, 2026: exercise meta-analysis
• Gorzko et al., Nutrients, 2026: probiotic trial
• Dincgez et al., Journal of Obstetrics and Gynaecology Research, 2026: CoQ10 and myo-inositol
• Perera et al., Advances in Therapy, 2026: berberine review
• Clift et al., Journal of the Endocrine Society, 2026: tirzepatide and weight
• Fayyaz et al., Nutrition, 2026: diet coaching
• Gambineri et al., Journal of Endocrinological Investigation, 2026: BMI and Rotterdam types
• Zhang et al., Clinica Chimica Acta, 2026: CLIA and LC-MS/MS
• Havers-Borgersen et al., European Journal of Preventive Cardiology, 2026: heart attack and stroke
• Alur-Gupta et al., Journal of Clinical Endocrinology and Metabolism, 2026: race and heart risk
• Forslund et al., Journal of Internal Medicine, 2026: heart risk review
• Moore et al., Cardiology in Review, 2026: heart risk review
• Rodriguez et al., Thrombosis Research, 2026: blood clots
• Alur-Gupta et al., Fertility and Sterility, 2026: cancer risk
• Samala et al., Hepatology, 2026: saroglitazar and liver fat
• Fornaro et al., European Neuropsychopharmacology, 2026: depression and anxiety rates
• Duval et al., Journal of Health Psychology, 2026: mindfulness and CBT
• Outreman et al., Gynecologie Obstetrique Fertilite and Senologie, 2026: SOLENCE app
• Shen et al., Journal of Nutrition Education and Behavior, 2026: habit change interviews
• Lingadal et al., Journal of the Endocrine Society, 2026: teen genetics
• Shi et al., eBioMedicine, 2026: teen blood tests
• Luciano et al., Journal of Clinical Endocrinology and Metabolism, 2026: early adrenarche
• Aktoz et al., Maturitas, 2026: EMAS menopause guide
• Mazza et al., Endocrine Practice, 2026: PMOS across the lifespan
• Vine et al., Advances in Nutrition, 2026: the name change and diet care
• Albaik et al., Archives of Osteoporosis, 2026: bone health
• Maity et al., Current Eye Research, 2026: dry eye
• Amiri et al., Journal of the Endocrine Society, 2026: dementia review
• Vagios et al., Journal of Assisted Reproduction and Genetics, 2026: lean and non-lean blood markers
• Dumesic et al., Fertility and Sterility, 2026: TyG-BMI in normal-weight women
• Bdeir et al., Annals of Medicine, 2026: vitamin D and inflammation
• Tanvir et al., Journal of Global Health, 2026: symptoms in Bangladesh
• Liu et al., Frontiers in Endocrinology, 2026: thyroid score
• Kowalczyk-Guzikowska et al., Ginekologia Polska, 2026: anti-inflammatory diet
• Wang et al., Food Science and Nutrition, 2026: plant flavonoids
• Unsal et al., Clinics in Dermatology, 2026: drinks and skin
• Kumari et al., Journal of Ayurveda and Integrative Medicine, 2026: yoga
• Zadeh et al., Journal of Exercise Science and Fitness, 2026: Nordic walking
• Dziewierz et al., Diabetes, Obesity and Metabolism, 2026: GLP-1 prescribing
• Prentice et al., Drug and Therapeutics Bulletin, 2026: drug treatment review
• Zhang et al., Obesity Surgery, 2026: sleeve gastrectomy
• Cherlin et al., eLife, 2026: pain

August 2026 edition:

• PeerJ, 2026: exercise and testosterone
• Diabetes, Obesity and Metabolism, 2026: metabolic stress testing
• Applied Psychology: Health and Well-Being, 2026: mindfulness
• Tirzepatide with metformin trial, 2026: weight and visceral fat
• Annals of African Medicine, 2026: metformin and leptin
• European Journal of Endocrinology, 2026: the pill and blood fats
• Raine Study cohort, 2026: childhood sleep
• Clinical Endocrinology, 2026: inositol and body weight

How this log is made

PCOS Meal Planner runs a PubMed scan every week. It scores each paper for relevance to food and treatment, for the strength of its design, and for whether it was done in humans. Animal and cell studies score low, because they rarely change what anyone should eat.

For this edition, 177 leads were screened and 45 were shortlisted. We read the abstract of every study we used. Every number on this page comes from the published abstract, not from a news story. We report sample size and the authors' own limits next to each result, even when the limits weaken it. When a study goes against advice we gave before, we say so here, as with berberine.

This page reports research. It is not medical advice. Do not start, stop or change a medicine or supplement because of it. Talk to a doctor who knows your history first.

Get the research that changes your plate

Research only helps when it reaches your kitchen. PCOS Meal Planner reads it so you do not have to, then turns the parts that matter into meals.

• Ask the PCOS Meal Planner AI how this month's findings apply to your week of meals.
• Build your free PCOS meal plan matched to your calorie target and your food dislikes.
• Read the evidence baseline in the best diet for PCOS in 2026.
• Follow our Telegram channel for each round of findings as it lands.